FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2972966903> ?p ?o ?g. }

• W2972966903 endingPage "1550" @default.
• W2972966903 startingPage "1540" @default.
• W2972966903 abstract "Spironolactone is effective at reducing blood pressure in patients with uncontrolled resistant hypertension. However, the use of spironolactone in patients with chronic kidney disease can be restricted by hyperkalaemia. We evaluated use of the potassium binder patiromer to allow more persistent use of spironolactone in patients with chronic kidney disease and resistant hypertension.In this phase 2 multicentre, randomised, double-blind, placebo-controlled study, we enrolled participants aged 18 years and older with chronic kidney disease (estimated glomerular filtration rate 25 to ≤45 mL/min per 1·73 m2) and uncontrolled resistant hypertension from 62 outpatient centres in ten countries (Bulgaria, Croatia, Georgia, Hungary, Ukraine, France, Germany, South Africa, the UK, and the USA). Patients meeting all eligibility criteria at the final screening visit were stratified by local serum potassium measurement (4·3 to <4·7 mmol/L vs 4·7 to 5·1 mmol/L) and history of diabetes. Participants were randomly assigned (1:1) with an interactive web response system to receive either placebo or patiromer (8·4 g once daily), in addition to open-label spironolactone (starting at 25 mg once daily) and their baseline blood pressure medications. Participants, the study team that administered treatments and measured blood pressure, and the investigators were masked to assigned treatment groups. Dose titrations were permitted after 1 week (patiromer) and 3 weeks (spironolactone). The primary endpoint was the between-group difference at week 12 in the proportion of patients on spironolactone. Efficacy endpoints and safety were assessed in all randomised patients (intention to treat). The study was registered with Clinicaltrials.gov, NCT03071263.Between Feb 13, 2017, and Aug 20, 2018, we screened 574 patients. 295 (51%) of 574 patients met all inclusion criteria and were randomly assigned to spironolactone in addition to double-blind treatment with either placebo (n=148) or patiromer (n=147). At week 12, 98 (66%) of 148 patients in the placebo group and 126 (86%) of 147 patients in the patiromer group remained on spironolactone (between-group difference 19·5%, 95% CI 10·0-29·0; p<0·0001). Adverse events were mostly mild or moderate in severity and occurred in 79 (53%) of 148 patients in the placebo group and 82 (56%) of 147 patients in the patiromer group.In patients with resistant hypertension and chronic kidney disease, patiromer enabled more patients to continue treatment with spironolactone with less hyperkalaemia. Persistent spironolactone enablement in this population of patients has clinical relevance for the treatment of resistant hypertension.Relypsa, a Vifor Pharma Group Company." @default.
• W2972966903 created "2019-09-19" @default.
• W2972966903 creator A5017971948 @default.
• W2972966903 creator A5021920910 @default.
• W2972966903 creator A5027309076 @default.
• W2972966903 creator A5031727063 @default.
• W2972966903 creator A5037834649 @default.
• W2972966903 creator A5056816871 @default.
• W2972966903 creator A5070514003 @default.
• W2972966903 creator A5086409547 @default.
• W2972966903 creator A5089305017 @default.
• W2972966903 date "2019-10-01" @default.
• W2972966903 modified "2023-10-11" @default.
• W2972966903 title "Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial" @default.
• W2972966903 cites W1756552807 @default.
• W2972966903 cites W1797367453 @default.
• W2972966903 cites W1889433649 @default.
• W2972966903 cites W1948592297 @default.
• W2972966903 cites W1970939567 @default.
• W2972966903 cites W1996348084 @default.
• W2972966903 cites W2034121292 @default.
• W2972966903 cites W2121169187 @default.
• W2972966903 cites W2164249826 @default.
• W2972966903 cites W2324948948 @default.
• W2972966903 cites W2584697073 @default.
• W2972966903 cites W2764179054 @default.
• W2972966903 cites W2768267412 @default.
• W2972966903 cites W2796868581 @default.
• W2972966903 cites W2885869386 @default.
• W2972966903 cites W2888589263 @default.
• W2972966903 cites W2892031176 @default.
• W2972966903 cites W2920258695 @default.
• W2972966903 doi "https://doi.org/10.1016/s0140-6736(19)32135-x" @default.
• W2972966903 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31533906" @default.
• W2972966903 hasPublicationYear "2019" @default.
• W2972966903 type Work @default.
• W2972966903 sameAs 2972966903 @default.
• W2972966903 citedByCount "199" @default.
• W2972966903 countsByYear W29729669032019 @default.
• W2972966903 countsByYear W29729669032020 @default.
• W2972966903 countsByYear W29729669032021 @default.
• W2972966903 countsByYear W29729669032022 @default.
• W2972966903 countsByYear W29729669032023 @default.
• W2972966903 crossrefType "journal-article" @default.
• W2972966903 hasAuthorship W2972966903A5017971948 @default.
• W2972966903 hasAuthorship W2972966903A5021920910 @default.
• W2972966903 hasAuthorship W2972966903A5027309076 @default.
• W2972966903 hasAuthorship W2972966903A5031727063 @default.
• W2972966903 hasAuthorship W2972966903A5037834649 @default.
• W2972966903 hasAuthorship W2972966903A5056816871 @default.
• W2972966903 hasAuthorship W2972966903A5070514003 @default.
• W2972966903 hasAuthorship W2972966903A5086409547 @default.
• W2972966903 hasAuthorship W2972966903A5089305017 @default.
• W2972966903 hasBestOaLocation W29729669032 @default.
• W2972966903 hasConcept C126322002 @default.
• W2972966903 hasConcept C142724271 @default.
• W2972966903 hasConcept C159641895 @default.
• W2972966903 hasConcept C168563851 @default.
• W2972966903 hasConcept C203092338 @default.
• W2972966903 hasConcept C204787440 @default.
• W2972966903 hasConcept C27081682 @default.
• W2972966903 hasConcept C2776379505 @default.
• W2972966903 hasConcept C2778198053 @default.
• W2972966903 hasConcept C2778653478 @default.
• W2972966903 hasConcept C2780243291 @default.
• W2972966903 hasConcept C71924100 @default.
• W2972966903 hasConcept C84393581 @default.
• W2972966903 hasConceptScore W2972966903C126322002 @default.
• W2972966903 hasConceptScore W2972966903C142724271 @default.
• W2972966903 hasConceptScore W2972966903C159641895 @default.
• W2972966903 hasConceptScore W2972966903C168563851 @default.
• W2972966903 hasConceptScore W2972966903C203092338 @default.
• W2972966903 hasConceptScore W2972966903C204787440 @default.
• W2972966903 hasConceptScore W2972966903C27081682 @default.
• W2972966903 hasConceptScore W2972966903C2776379505 @default.
• W2972966903 hasConceptScore W2972966903C2778198053 @default.
• W2972966903 hasConceptScore W2972966903C2778653478 @default.
• W2972966903 hasConceptScore W2972966903C2780243291 @default.
• W2972966903 hasConceptScore W2972966903C71924100 @default.
• W2972966903 hasConceptScore W2972966903C84393581 @default.
• W2972966903 hasIssue "10208" @default.
• W2972966903 hasLocation W29729669031 @default.
• W2972966903 hasLocation W29729669032 @default.
• W2972966903 hasLocation W29729669033 @default.
• W2972966903 hasLocation W29729669034 @default.
• W2972966903 hasOpenAccess W2972966903 @default.
• W2972966903 hasPrimaryLocation W29729669031 @default.
• W2972966903 hasRelatedWork W1487494130 @default.
• W2972966903 hasRelatedWork W1976906202 @default.
• W2972966903 hasRelatedWork W2004469605 @default.
• W2972966903 hasRelatedWork W2119084971 @default.
• W2972966903 hasRelatedWork W2145027707 @default.
• W2972966903 hasRelatedWork W2493395454 @default.
• W2972966903 hasRelatedWork W2892031176 @default.
• W2972966903 hasRelatedWork W2967580321 @default.
• W2972966903 hasRelatedWork W3031829024 @default.
• W2972966903 hasRelatedWork W3119032197 @default.
• W2972966903 hasVolume "394" @default.

• next